Skip to main content

Key Product Details

Species Reactivity

Human

Applications

CyTOF-ready, Flow Cytometry, Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 89106

Product Summary for Human VEGFR2/KDR/Flk-1 Antibody

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGFR2/KDR/Flk-1
Ala20-Glu764
Accession # P35968

Specificity

Detects human VEGFR2/KDR/Flk-1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) VEGFR1, rhVEGFR3 or recombinant mouse VEGFR2 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Human VEGFR2/KDR/Flk-1 Antibody

Detection of VEGFR2/KDR/Flk-1 antibody in HUVEC Human Cells antibody by Flow Cytometry.

Detection of VEGFR2/KDR/Flk‑1 in HUVEC Human Cells by Flow Cytometry.

HUVEC human umbilical vein endothelial cells were stained with Mouse Anti-Human VEGFR2/KDR/Flk-1 Monoclonal Antibody (Catalog # MAB3572, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B).
VEGFR2/KDR Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Human VEGFR2/KDR Antibody.

VEGFR2/KDR Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Human VEGFR2/KDR Antibody.

Recombinant Human VEGFR2/KDR Fc Chimera (Catalog # 357-KD) inhibits Recombinant Human VEGF165(Catalog # 293-VE) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Human VEGF165(10 ng/mL) activity elicited by Recombinant Human VEGFR2/KDR Fc Chimera (50 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human VEGFR2/KDR Monoclonal Antibody (Catalog # MAB3572). The ND50 is typically 10-50 ng/mL.

Applications for Human VEGFR2/KDR/Flk-1 Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/106 cells
Sample: HUVEC human umbilical vein endothelial cells

Neutralization

Measured by its ability to neutralize VEGFR2/KDR/Flk‑1-mediated inhibition of proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 10-50 ng/mL in the presence of 50 ng/mL Recombinant Human VEGFR2/KDR/Flk‑1 Fc Chimera and 10 ng/mL Recombinant Human VEGF165.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 1 review rated 5 using MAB3572 in the following applications:

Published Applications

Read 24 publications using MAB3572 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mature VEGFR2 is composed of a 745 aa extracellular domain, a 25 aa transmembrane domain and a 567 aa cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References

  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Alternate Names

CD309, Flk-1, Flk1, KDR, KRD1, Ly73, VEGF R2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Gene Symbol

KDR

UniProt

Product Documents for Human VEGFR2/KDR/Flk-1 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human VEGFR2/KDR/Flk-1 Antibody

For research use only

Loading...
Loading...

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

÷
=
Loading...
Setting the standard in quality research reagents